Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis
NCT05247216Phase 2Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hemay007 in rheumatoid arthritis (RA), sponsored by Tianjin Hemay Biotech. Started Mar 2021; status: completed.
02
Drugs
hemay007
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05247216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247216.